Benzinga | Feb 3, 2021 07:03AM EST

Abzena Selected by Immunome To Develop And Manufacture Antibody Cocktail For Immunome's COVID-19 Antibody Based Treatment

Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena was selected as Immunome's partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens. Abzena will work with Immunome to produce the antibody cocktail for clinical testing. In July 2020, Immunome was awarded a $13.3 million agreement executed by the United States Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support this program.